[CLSTR]
API
< Back to situations

[ORGANIZATION]

AbbVie

Featured in 49 tracked stories · first seen

Situations

[ACTIVE] [BUSINESS] [US]

AbbVie financial performance and strategic transition

2 clusters · 8 sources · last updated

Latest: AbbVie raises profit guidance following strong Q3 results

AbbVie is undergoing a strategic shift in its pharmaceutical focus, moving from its legacy product Humira toward new immunology and oncology treatments. In fiscal year 2025, the company reported revenue of $61.2 billion,

[ACTIVE] [HEALTH] [BR] [CL] [ES]

Brazil cancer burden, screening, treatment & legislation

35 clusters · 207 sources · last updated

Latest: Cancer awareness and personal resilience stories highlight health importance

Brazil is advancing legislative and policy measures to address its rising cancer burden. The Senate's Social Affairs Commission (CAS) is reviewing a project to improve the National Cancer Patient Navigation Program to op

[ACTIVE] [HEALTH] [ES]

Hematology and thrombosis congresses in Bilbao

2 clusters · 3 sources · last updated

Latest: AbbVie presents hematological cancer research in Bilbao

The LXVIII National Congress of the Spanish Society of Hematology and Hemotherapy (SEHH) and the XLII National Congress of the Spanish Society of Thrombosis and Hemostasis (SETH) convened at the Bilbao Exhibition Centre

[QUIET] [HEALTH] [BR] [PY] [FR]

Brazil ANVISA expands product safety enforcement

43 clusters · 290 sources · last updated

Latest: Anvisa bans Accu-Chek Active glucose test strips on Amazon

Since May 2026, Brazil’s National Health Surveillance Agency (ANVISA) has intensified enforcement of sanitary rules for pharmaceuticals, cosmetics, and consumer goods. Early actions included suspending batches of statins

[QUIET] [HEALTH] [US]

Clinical efficacy of upadacitinib in dermatological studies

2 clusters · 6 sources · last updated

Latest: Upadacitinib shows promise in treating severe alopecia areata

Clinical research has highlighted the efficacy of the medication upadacitinib across different dermatological conditions. In studies regarding atopic dermatitis, data presented at the 2026 Fall Clinical Dermatology Conf

[QUIET] [BUSINESS]

AbbVie IBD treatment clinical efficacy data

2 clusters · 5 sources · last updated

Latest: AbbVie reports clinical remission data for IBD treatments

AbbVie has presented new clinical data regarding the efficacy of its inflammatory bowel disease (IBD) treatments, specifically risankizumab (SKYRIZI) and upadacitinib (RINVOQ), for patients with Crohn’s disease and ulcer

[QUIET] [POLITICS] [US]

US pharmaceutical industry and Trump political rhetoric

2 clusters · 14 sources · last updated

Latest: Donald Trump pharmaceutical investments face scrutiny amid Medicare exemption claims

Donald Trump has utilized his political platform to address the opioid epidemic and pharmaceutical drug pricing, claiming his administration achieved the ‘greatest reduction’ in prescription costs. He has also used trade

[QUIET] [BUSINESS] [DE] [US] [CN]

Global pharmaceutical market trends

2 clusters · 4 sources · last updated

Latest: Parkinson’s disease market projected to reach $7.2 billion by 2033

The provided data outlines growth projections and regulatory developments across different therapeutic sectors. In the non-small cell lung cancer (NSCLC) market, PD-1 therapies are projected to grow from $27.5 billion

[QUIET] [HEALTH]

JAK inhibitor use in dermatological treatments

2 clusters · 4 sources · last updated

Latest: JAK inhibitors recommended over systemic steroids for skin conditions

Medical professionals are increasingly advocating for the use of Janus kinase (JAK) inhibitors as a primary treatment for skin conditions such as vitiligo, atopic dermatitis (AD), and alopecia areata. In the treatment

[QUIET] [TECHNOLOGY] [US] [DE] [DK]

AI and automation in antibody discovery

2 clusters · 5 sources · last updated

Latest: Danaher to launch AI-powered autonomous antibody lab in 2027

The biotechnology sector is increasingly integrating artificial intelligence and automation to enhance antibody discovery and development. In late September 2026, Ginkgo Datapoints and Apheris launched the Antibody Dev

[QUIET] [HEALTH] [CN] [EU] [IT]

Upadacitinib expanded approval for skin and arthritis

4 clusters · 22 sources · last updated

Latest: European Commission approves upadacitinib for three immune-mediated diseases

Clinical trials for the Janus kinase (JAK) inhibitor upadacitinib have demonstrated success in treating severe alopecia areata by blocking inflammatory signals via the JAK/STAT pathway. Research indicates that up to 23 p

Also covered in